Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?

Nov 26 2022

• By Derrick Gingery

gene therapy — • Source: Shutterstock

Related Content

CBER/CDER Transition Begins In June: Application Assignments “99.99%” Set

Mar 24 2003

Combo-Product Sponsors Could More Easily Get Device Designation At US FDA

Jul 29 2018

US FDA Preparing For New 'Combination Product Agreement Meetings'

Oct 22 2018

PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention

Nov 11 2020

Gene Therapy Manufacturing Hurdle: Sponsors Unwilling To Share ‘Secret Sauce’

Aug 10 2020

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Aug 23 2021

CBER Reorganization Aims To Fight Recruitment Challenges, Tackle Upcoming Gene Therapy Wave

Jan 12 2022

New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges

Oct 05 2022

After ‘Clean’ User Fee Renewal, Will Programs Held Hostage Be Enough To Drive A Broader Reform Bill?

Sep 28 2022

US FDA’s Reclassification Of Certain Drugs As Devices May Be 'Seismic Event' For Some

Feb 08 2022

Requiring FDA Guidances Does Not Always Advance The Science, Gene Therapy Director Says

Oct 13 2022

Additional Topics

United States Gene Therapy Manufacturing Review Pathway Regulation Biologics BioPharmaceutical Combination Products Outlook 2023

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window